We recognise that to ensure our long-term success as a business, as well as a continued positive impact on patients, healthcare systems, the environment and society, it’s vital that we listen to, understand, and engage with the views and expectations of our stakeholders.
At AstraZeneca, sustainability is at the core of our business strategy as well as our approach as a company. It’s therefore critical that we have a comprehensive understanding of the ESG (Environmental, Social and Governance) issues that matter most for our stakeholders - from current and future employees, to investors, policy makers, non-governmental organisations, academia, and many more. Diverse voices and perspectives are key for us as a global biopharmaceuticals company which operates in over 100 countries.
To define the sustainability issues that matter most to AstraZeneca and our stakeholders, and to continue to progress our sustainability agenda, we conduct a Materiality Assessment every few years. This Assessment shines a spotlight on the associated opportunities and risks which these issues present to our business – today and in the future. In turn, the Materiality Assessment informs our sustainability strategy by helping us prioritise issues where we have the greatest capacity for positive health, societal, environmental and economic impacts.